Research programme: antiviral therapeutics - Coley Pharmaceuticals
Alternative Names: CpG DNALatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Coley Pharmaceutical Group
- Developer Coley Pharmaceutical GmbH
- Class Nucleotides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Orthopoxvirus infections; Viral infections
Most Recent Events
- 01 Jan 2008 Coley Pharmaceutical Group has been acquired by Pfizer
- 03 May 2007 Preclinical trials in Orthopoxvirus infections in USA (unspecified route)
- 03 May 2007 Preclinical trials in Viral infections in USA (unspecified route)